CD23 expression in lymphoplasmacytic lymphoma: Clinical–pathological and biological correlations
Histopathology · 2025
DOI: 10.1111/his.15401 ↗At a glance
Journal article in Histopathology, 2025. Written by Marco Pizzi and 12 co-authors. Institution: Pathology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, Padua, Italy. Major MEDLINE topics: Waldenstrom Macroglobulinemia, Biomarkers, Tumor, Lymphoma, B-Cell, Marginal Zone, Receptors, IgE. Cited 1 times so far (Crossref); 22 references.
Abstract (original language)
Aims
The diagnosis of lymphoplasmacytic lymphoma (LPL) in the bone marrow (BM) is challenged by aberrant phenotypes and by overlapping histological features with marginal zone lymphoma (MZL). To address these issues, we (i) assessed LPL immunophenotype on a large series of BM samples, (ii) drew possible correlations between LPL phenotype and clinical/molecular data and (iii) investigated the role of new phenotypical markers in the differential diagnosis between LPL and MZL. Materials and methods The study retrospectively considered 81 clinically annotated LPL diagnosed at Padua University Hospital (Padua, Italy) during a 5‐year period. BM findings were correlated with clinical laboratory findings and with MYD88 and CXCR4 mutational status. The obtained results were compared with a series of 77 MZL in the BM, including 46 splenic MZL (SMZL), 14 nodal MZL (NMZL) and 17 extra‐nodal MZL (EMZL).
Results
The LPL cohort included 52 males and 29 females (median age at diagnosis = 71 years). Aberrant CD10 and CD5 positivity was documented in 3 of 81 (3.7%) and 13 of 81 (16.1%) cases, respectively. CD23 positivity occurred in 56 of 81 (69.1%) cases, being usually partial/focal. CD23 expression did not correlate with any specific clinical–pathological parameter. Comparison with SMZL, NMZL and EMZL highlighted less frequent splenomegaly, higher serum paraprotein, higher CD23 expression and fewer follicular dendritic cell networks in LPL. A combined clinical–pathological score supported the differential diagnosis between LPL and MZL of any type. The highest diagnostic yield was obtained for the differential diagnosis between LPL and SMZL.
Conclusions
Partial positivity for CD23 is a common feature of LPL in the BM. Together with other clinical and histological parameters, CD23 expression supports the differential diagnosis between LPL and MZL.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Pathology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, Padua, Italy.
- Hematology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, Padua, Italy.
- 1st Medical Clinic, Department of Medicine-DIMED, University of Padua School of Medicine, Padua, Italy.
ORCID profiles: Marco Pizzi
Cite
APA
Pizzi, M., Danesin, N., Scarmozzino, F., Pinto, M., Scapinello, G., Santoro, L., Bertozzi, I., Arcidiacono, G. P., Trimarco, V., Visentin, A., Trentin, L., Piazza, F., & Dei Tos, A. P. (2025). CD23 expression in lymphoplasmacytic lymphoma: Clinical–pathological and biological correlations. Histopathology. https://doi.org/10.1111/his.15401
Vancouver
Pizzi M, Danesin N, Scarmozzino F, Pinto M, Scapinello G, Santoro L, et al. CD23 expression in lymphoplasmacytic lymphoma: Clinical–pathological and biological correlations. Histopathology. 2025. doi:10.1111/his.15401
BibTeX
@article{Pizzi2025,
author = {Pizzi, Marco and Danesin, Nicolò and Scarmozzino, Federico and Pinto, Martina and Scapinello, Greta and Santoro, Luisa and Bertozzi, Irene and Arcidiacono, Gaetano Paride and Trimarco, Valentina and Visentin, Andrea and Trentin, Livio and Piazza, Francesco and Dei Tos, Angelo Paolo},
title = {CD23 expression in lymphoplasmacytic lymphoma: Clinical–pathological and biological correlations},
journal = {Histopathology},
year = {2025},
doi = {10.1111/his.15401}
}
EUVIMED